BMC
IMNM icon

Bear Mountain Capital’s Immunome IMNM Stock Holding History

Bear Mountain Capital’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$452 Hold
20
– – ﹤0.01% 168
2026
Q1 		$485 Hold
20
– – ﹤0.01% 154
2025
Q4 		$457 Hold
20
– – ﹤0.01% 156
2025
Q3 		$335 Hold
20
– – ﹤0.01% 230
2025
Q2 		$212 Hold
20
– – ﹤0.01% 165
2025
Q1 		$171 Hold
20
– – ﹤0.01% 322
2024
Q4 		$204 Buy
+20
New +$242 ﹤0.01% 161

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Bear Mountain Capital's IMNM Position: Q2 2026 in Review

Bear Mountain Capital held its Immunome (IMNM) position steady in Q2 2026 at 20 shares worth $452. The position accounts for ﹤0.01% of the portfolio, ranked #168.

Bear Mountain Capital first reported a position in IMNM in Q4 2024 and has held it in 7 quarters since. The position peaked at $485 in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Bear Mountain Capital held 20 shares of Immunome worth $452 as of Q2 2026.
  • Bear Mountain Capital left its Immunome share count unchanged in Q2 2026.
  • Immunome made up ﹤0.01% of Bear Mountain Capital's portfolio in Q2 2026, its #168 holding.
  • Bear Mountain Capital first reported a position in Immunome in Q4 2024 and has held it in 7 quarters since.
  • Bear Mountain Capital's Immunome position peaked at $485 in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Bear Mountain Capital's 13F filing for Q2 2026, filed 20 Jul 2026.